New nasal spray aims to calm social anxiety in minutes
NCT ID NCT05011396
First seen Dec 26, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tested a nasal spray called PH94B to see if it could quickly reduce anxiety during a public speaking task in adults with social anxiety disorder. About 228 participants were randomly assigned to receive either the spray or a placebo, then asked to give a short speech. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
VistaGen Clinical Center
Allentown, Pennsylvania, 18104, United States
-
VistaGen Clinical Site
Phoenix, Arizona, 85012, United States
-
VistaGen Clinical Site
Garden Grove, California, 92845, United States
-
VistaGen Clinical Site
Oceanside, California, 92056, United States
-
VistaGen Clinical Site
Temecula, California, 92591, United States
-
VistaGen Clinical Site
Alpharetta, Georgia, 30022, United States
-
VistaGen Clinical Site
Prairie Village, Kansas, 66208, United States
-
VistaGen Clinical Site
Boston, Massachusetts, 02131, United States
-
VistaGen Clinical Site
Flowood, Mississippi, 39232, United States
-
VistaGen Clinical Site
Berlin, New Jersey, 08009, United States
-
VistaGen Clinical Site
Brooklyn, New York, 11235, United States
-
VistaGen Clinical Site
New York, New York, 10032, United States
-
VistaGen Clinical Site
Rochester, New York, 14618, United States
-
VistaGen Clinical Site
Memphis, Tennessee, 38119, United States
-
VistaGen Clinical Site
Austin, Texas, 78737, United States
Conditions
Explore the condition pages connected to this study.